The British Standards Institution (BSI) and the Alliance for Clinical Research Excellence and Safety (ACRES) announce a multi-stakeholder collaboration to develop global standards of excellence for clinical research sites and lay the groundwork for site-recognition and accreditation.
London-based British Standards Institution (BSI), a leader in promoting excellence through standards development for business processes globally, and Massachusetts-based Alliance for Clinical Research Excellence and Safety (ACRES), a multi-sector collaborative building a global system for clinical research, today announced a major strategic partnership to promote excellence and improve quality and efficiency in medical product development worldwide. BSI joins ACRES ongoing Site Accreditation and Standards Initiative (SASI) with the intention to develop and implement standards of excellence for clinical research sites and engage with all parties of the clinical research endeavor to develop an innovative process for “dynamic accreditation” of research sites that will promote, recognize and reward excellence.
BSI and ACRES also announced their intention to create professional stakeholder groups to oversee and maintain the standards, and to operate the global accreditation process.
Formed in 1901 as the world’s first national standards body and providing services to more than 70,000 sites in 150 countries across a range of industry sectors, BSI brings deep experience in standards development and accreditation processes to ACRES efforts. BSI and ACRES will work with stakeholders from across the clinical research endeavor in developing both the standards and the system for independent third-party accreditation.
Gary Slack, SVP for Global Healthcare at BSI, announced the new partnership, noting “BSI believes excellence must be a habit, that excellence and responsibility must be embedded in sustainable business practices, and by doing so, improved quality and effectiveness are not just achieved, they are inevitable. We share these beliefs with ACRES and are excited to be part of these long-overdue efforts.”
SASI, building on its previous efforts in surveying and consulting on current site quality criteria, is constructing a comprehensive set of standards covering essential domains of patient and subject engagement and protection, site personnel, research integrity, facilities, information systems and data management, management and administration as well as quality management. These standards and derived metrics will enable an innovative ‘dynamic accreditation’ process that automatically monitors operational data in real time to continuously improve site and system performance, benefitting stakeholders while minimizing research site burdens.
“High-performing quality research sites are critical elements in a safe, effective system for testing new medical products and doing clinical research to develop new therapies. For too long we have failed to recognize and reward truly excellent, professional sites and lacked a system for doing so. No more--this is true transformational change, a new way of doing things, and the expertise that BSI brings to ACRES global collaboration brings the future much closer than anyone could have imagined”, said ACRES president and co-founder, Dr. Greg Koski.
Arti Bajpai, co-chair of ACRES Global Standards Working Party developing the standards, commented “ACRES will not itself create nor hold the standards-as an enterprise-wide effort, everyone-sites, sponsors, CROs, ethics review committees, patients, providers and regulators-has a stake in the standards. Like the accreditation process itself, they too must be dynamic.” Bajpai, president of Pennsylvania-based Compliance and Quality Integration (CQI) Consulting, and co-chair Dr. Amir Kalali, Head of the Neuroscience Center of Excellence at Quintiles and co-founder of CNS Summit, are currently assembling domain-specific standards teams to coordinate and evaluate the new standards, targeted for public comment and evaluation in 2016.
ACRES
The Alliance for Clinical Research and Excellence (ACRES) is a non-profit leveraging the expertise of stakeholders worldwide to collaboratively build a shared global system for clinical trials that are responsibly conducted according to the highest standards of safety, quality and efficiency, based in principles of Accountable Research™. Adapting lessons from industries successfully implementing principles of systems and safety engineering, this system will employ integrated information technologies as well as interoperable standards, policies and practices to enhance clinical research safety, quality and efficiency worldwide. For more information, please contact Dr. Mary Tobin at mtobin(at)acresglobal(dot)net.
BSI
The world’s first standards organization, BSI now delivers a comprehensive business services portfolio to clients, helping them raise their performance and enhance their competitiveness worldwide, currently publishing over 2,500 standards annually and originating many of the world’s most commonly management systems standards, including work on clinical research safety and quality standards for medical devices]. BSI’s values of integrity, continual improvement and inclusivity ensure BSI operates in a socially responsible way. For more information, please contact the BSI press office pressoffice(at)bsigroup(dot)com or +44 20 8996 6330.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.